Skip to content

Mindfulness-based cognitive therapy for preventing relapse in recurrent depression: A randomized dismantling trial.

J. Mark G. Williams, Catherine Crane, Thorsten Barnhofer, Kate Brennan, Danielle S. Duggan, Melanie Fennell, Ann Hackmann, Adele Krusche, Kate Muse, Isabelle Rudolf von Rohr, Dhruvi Shah, Rebecca S. Crane, Catrin Eames, Mariel Jones, Sholto Radford, Sarah Silverton, Yongzhong Sun, Elaine Weatherley-Jones, Christopher J. Whitaker, Daphne Russell, Ian Russell

Journal of Consulting and Clinical Psychology December 3, 2013 DOI: 10.1037/a0035036 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 274
Population People in remission from major depressive disorder following at least 3 previous episodes
Interventions Mindfulness-based cognitive therapy Cognitive psychological education
Duration 8-week intervention, 12-month follow-up
Topics Meditation Depression
Keywords Mindfulness-based cognitive therapy Randomized controlled trial Hazard ratio Relapse prevention Clinical psychology Confidence interval
Citations 418
Post-publication review 1 comment on PubPeer (opens in new tab) · last active September 2016
Key findings MBCT significantly protected against relapse only for participants with above-average childhood trauma severity, but showed no overall advantage over CPE or TAU.

Abstract

Objective: We compared mindfulness-based cognitive therapy (MBCT) with both cognitive psychological education (CPE) and treatment as usual (TAU) in preventing relapse to major depressive disorder (MDD) in people currently in remission following at least 3 previous episodes.

Method: A randomized controlled trial in which 274 participants were allocated in the ratio 2:2:1 to MBCT plus TAU, CPE plus TAU, and TAU alone, and data were analyzed for the 255 (93%; MBCT = 99, CPE = 103, TAU = 53) retained to follow-up. MBCT was delivered in accordance with its published manual, modified to address suicidal cognitions; CPE was modeled on MBCT, but without training in meditation. Both treatments were delivered through 8 weekly classes.

Results: Allocated treatment had no significant effect on risk of relapse to MDD over 12 months follow-up, hazard ratio for MBCT vs. CPE = 0.88, 95% CI [0.58, 1.35]; for MBCT vs. TAU = 0.69, 95% CI [0.42, 1.12]. However, severity of childhood trauma affected relapse, hazard ratio for increase of 1 standard deviation = 1.26 (95% CI [1.05, 1.50]), and significantly interacted with allocated treatment. Among participants above median severity, the hazard ratio was 0.61, 95% CI [0.34, 1.09], for MBCT vs. CPE, and 0.43, 95% CI [0.22, 0.87], for MBCT vs. TAU. For those below median severity, there were no such differences between treatment groups.

Conclusion: MBCT provided significant protection against relapse for participants with increased vulnerability due to history of childhood trauma, but showed no significant advantage in comparison to an active control treatment and usual care over the whole group of patients with recurrent depression.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics